Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Determining the prognosis of patients with myelodysplastic syndromes using machine learning

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 02.12.18
Views: 605

Dr Aziz Nazha - Cleveland Clinic, Cleveland, USA

Dr Aziz Nazha speaks to ecancer at ASH 2018 about the use of machine learning in determining the prognosis of patients with myelodysplastic syndromes. 

He explains that using a machine learning algorithm improves prognosis accuracy for these patients.

Dr Nazha concludes that while there have been advancements in personalised medicine and treatments, personalised diagnosis is also very important.

Watch his press conference here.

Read more about this work here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation